Aim: To assess the comparative effects of glucose-lowering drugs (GLDs) on the risk of diabetic retinopathy (DR) in patients with type 2 diabetes mellitus (T2DM).
| INTRODUCTION
Diabetic retinopathy (DR) is the most common microvascular complication in patients with diabetes mellitus (DM) and the most frequent cause of blindness in adults. [1] [2] [3] Studies demonstrate that intensive glycaemic control reduces the risk of long-term complications such as retinopathy, neuropathy and nephropathy. [4] [5] [6] Improving glycaemic control also reduces DR progression. 7 However, a recent clinical trial of semaglutide (SUSTAIN -6) 8 showed an increased risk of developing DR and the complications of DR (defined as the need for retinal photocoagulation or treatment with intravitreal agents, vitreous hemorrhage or onset of blindness) among subjects treated with semaglutide, compared to subjects receiving placebo. In addition, some observational studies found that use of thiazolidinediones was associated with increased risk of diabetic macular edema (DME). 9, 10 In contrast, a pre-clinical study showed that control of hyperglycaemia with ipragliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, slowed the progression of retinopathy, nephropathy and neuropathy. 11 Huilin Tang and Guangyao Li contributed equally to this work, and are listed as co-first authors.
| Search strategy and study selection
We comprehensively searched PubMed, Embase, Cochrane Central
Register of Controlled Trials (CENTRAL) and Clinicaltrials.gov from inception to January 17, 2017 to identify eligible RCTs. A detailed search strategy that included electronic databases and key terms is presented in Appendix S1. There were no restrictions regarding language, date or publication. In addition, we identified other potential trials by manually searching the reference lists of included trials and relevant meta-analyses.
Two reviewers (Y. Z. and G. L.) independently selected the trials based on the following inclusion criteria: (1) RCTs that compared 1 or more GLDs with placebo, no treatment or active treatments, including DPP-4i, GLP-1RA, SGLT2 inhibitors, glinides, α-glucosidase inhibitors, thiazolidinediones, sulfonylureas, metformin and insulin. When background therapy was specified, we required this to be identical between the intervention and control groups; (2) trial durations ≥24 weeks; and (3) trials reporting safety outcomes of DR, including macular edema, vitreous hemorrhage, onset of diabetes-related blindness, and the need for treatment with an intravitreal agent or retinal photocoagulation. Authors were contacted for further information if necessary. Data from the large trials (EMPA-REG OUTCOME, 13 LEADERS, 14 showed that the incidence of DR ranged from 3 to 14.9 cases/1000 person-years. In studies with a population >1000 patients and no reported DR events, we assumed that DR events were underreported, and we contacted study authors to make inquiries. In these cases, 6 of 20 authors contacted responded; among these, 5 provided additional data and 1 clarified data.
| Data extraction and quality assessment
Two reviewers (Y. Z. and G. L.) independently extracted data from original trial reports using a standardized form. Data extracted included study characteristics (first author, publication year, NCT number and duration of follow-up) and patient characteristics (inclusion criteria, background treatments, mean age, proportion of men, duration of T2DM, baseline HbA1c % and body mass index, any GLD, comparators and incidence of DR). If multiple reports from the same population were retrieved, only the most complete and/or most recently reported data were used. If DR events were not reported in the manuscripts, we extracted the data from the "Serious Adverse
Events" section on ClinicalTrials.gov. When data were not consistent between the publication and the online source, we contacted the authors for verification.
Study quality was assessed by 2 reviewers using the Cochrane risk of bias tool as described in the Cochrane Collaboration Handbook. 15 In cases of disagreement, a third reviewer (T. W.) was consulted to reach a consensus. We assessed the risk of bias based on the following domains: random sequence generation (selection bias), allocation concealment (selection bias), blinding (performance bias and detection bias), incomplete outcome data (attrition bias) and selective reporting (reporting bias). We generated the risk of bias graphs using Review Manager 5.3 software, with each domain judged as low risk, high risk or unclear risk.
| Statistical analysis
Direct meta-analysis was carried out using Mantel-Haenszel's method with random effects models to calculate the odds ratio (ORs) and 95% confidence intervals (CIs) for direct comparisons between therapeutic regimens. Statistical heterogeneity was assessed using the I 2 statistic, with I 2 of <25%, ≥25% and <75%, and ≥75% indicating low, medium and high heterogeneity, respectively. 16 For comparisons including more than 10 trials, publication bias was evaluated using funnel-plot symmetry and Egger regression. A sensitivity analysis using person-years was performed to test the robustness of the results.
For indirect and mixed comparisons, a network meta-analysis with a random-effects model using the "mvmeta" command and programmed STATA routines was used to calculate ORs and 95% CIs between different interventions. 17, 18 For zero-event RCTs, a 0.5 zero-cell correction was applied before meta-analysis. 19 The relative ranking of GLDs on DR events was assessed by using their surface under the cumulative ranking curve (SUCRA), which represents their likelihood of being ranked safest. In this study, larger SUCRA probabilities indicate lower risk of DR events. 20 The heterogeneity variance (tau) estimated by a restricted maximum likelihood method was employed to investigate between-study heterogeneity in the network meta-analysis. 21 To check for the presence of inconsistency, a loop inconsistency-specific approach was introduced to evaluate the difference between direct and indirect estimates for a specific comparison. 22 To check the assumption of consistency in the entire network, a design-by-treatment interaction model involving the χ 2 test was used. 23 Finally, a comparison-adjusted funnel plot was used to assess small study effects within a network of interventions. 24 We performed a regression analysis to examine the relationship between trial characteristics and effect size using the following factors: duration of diabetes, difference in change in glycaemic control between groups, absolute glycaemic control achieved in the experimental treatment group and baseline systolic blood pressure. All meta-analyses were performed using STATA (Version 14; Stata Corp., College Station, Texas) and SAS version 9.4 (SAS Institute, Cary, N orth Carolina). A 2-tailed P < .05 was considered statistically significant.
3 | RESULTS 3.1 | Study selection and study characteristics Figure 1 shows the process of identifying eligible trials. We retrieved 11 428 studies through our electronic search and selected 1692 potential trials. Eight months after our formal search, the results of the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)
were published in September 2017. 25 We incorporated data from this large trial, and our final analysis included 36 manuscripts involving 37 trials 13, 14, ( Figure 1 ). These included 34 2-group trials, 2 3-group trials 46 ,48 and 1 4-group trial. 57 The available direct comparisons and network of trials are shown in Figure 2 .
We summarize the study characteristics in Table 1 Egger's test (P = .67), and visual inspection of the funnel plot (Appendix S7).
| Network meta-analysis
In the network meta-analysis (Appendix S8), sulfonylureas were associated with a significantly increased risk of DR as compared with both placebo (OR, 1.67; 95% CI, 1.01-2.76) ( and indirect estimates (all 95% CIs across zero) (Appendix S10) and no global inconsistency within any network (P = .80). In addition, the comparison-adjusted funnel plot indicated the absence of small-study effects (Appendix S11).
| Regression analysis
In the multivariate regression of 11 trials (studies with missing variables were excluded), none of the pre-specified factors were found to be significant (Appendix S12). In the univariate regression of 22 trials, the risk of DR was associated with difference in HbA1c % change between groups (P = .04) ( Figure 3 ).
| DISCUSSION
Our study is the first network meta-analysis to address the safety of GLDs concerning DR events. We included 37 RCTs that reported 1806 events among 100 928 patients with T2DM. In the network meta-analysis based on direct and indirect evidence, we found that the risk of DR events with both DPP-4i and GLP-1RA was similar to that with placebo. However, in the pairwise meta-analysis, there was a significantly increased risk of DR associated with DPP-4i alone.
There was also no significant association between SGLT2 inhibitors and risk of DR. In contrast, sulfonylureas were associated with a significantly increased risk of DR compared to placebo and SGLT2 inhibitors. Our univariate regression showed that the difference in HbA1c
% change between groups might be associated with DR risk (ie, the greater reduction in HbA1c %, the lower the risk of DR). This finding is consistent with current evidence, 7, 58 and confirms the importance of achieving good glycaemic control to reduce the risk of DR. However, none of these pre-specified factors was found to be significant in the multivariate regression, which might be explained, in large part, by the limited number of trials included in our metaanalysis.
In contrast to results from the SUSTAIN -6 8 and TECOS 26 studies, the results from our network meta-analysis found no significant increase in the risk of DR in patients using DPP-4i or GLP-1RA,
although an increased risk of DR associated with DPP-4i was detected in the pairwise meta-analysis, which was largely driven by No publications were found, and last updated data at ClinicalTrials.gov was extracted.
data from the TECOS 26 study. Recent evidence concerning the effects of incretin therapies on the microcirculation is scarce. Preclinical data demonstrated beneficial pleiotropic effects of incretin therapies on DR, independent of the glucose-lowering effect resulting from reducing blood-retinal barrier breakdown, inflammation and neuronal cell death. [59] [60] [61] [62] Topical administration of DPP-4i was shown to prevent neurodegeneration and vascular leakage in db/db mice by enhancing GLP-1. 63 The results in patients with T2DM remain inconsistent. In 2 small clinical studies, 2 DPP-4i (saxagliptin and vildagliptin) were found to reduce retinal capillary blood blow and improve vasodilation. 64, 65 In contrast, some GLP-1RAs (liraglutide and exenatide) and 1 DPP-4i (sitagliptin) had no effect on capillary perfusion in patients with T2DM. 66 Although some experimental studies and small clinical trials indicated overall beneficial effects on the development of DR with GLP-1RA and DPP-4i, this is balanced by evidence of progressive worsening or a net neutrality of these agents on DR. 67 Varadhan et al. found a progressive worsening of DR in patients treated for at least 6 months with exenatide. 68 The authors suggested that the worsening of DR might be explained by the sudden and substantial reduction in HbA1c levels (initial HbA1c decrease of ≥1.5%)
caused by treatment, 69 and subsequently found this effect to be transient and that continued therapy with exenatide was associated with a reversal of this phenomenon. 68 Several possible explanations for this observed phenomenon may lie in the short follow-up. Generally, 5 years is considered sufficient time to separate the incidence of DR between intervention and control groups. 67 However, the median duration of follow-up in the included RCTs was 1.5 years (range, 0.5-5.5 years). Finally, a lack of data on the grading of DR at baseline and during follow-up were reported in the clinical trials. 67 Further studies are required to clarify the risk of DR associated with DPP-4i or GLP-1RA.
Our meta-analysis found that SGLT2 inhibitors were similar to placebo concerning risk of DR. However, SGLT2 inhibitors were associated with the lowest risk among the GLDs in our network metaanalysis. Recently, several studies explored the mechanism behind the beneficial effect of SGLT2 inhibitors on DR. One small trial involving 59 patients found that dapagliflozin, 10 mg/d administered for 6 weeks, significantly lowered retinal capillary flow compared to little change in the placebo group. 70 In addition, dapagliflozin appeared to prevent changes to the structure of the retinal arterioles. 70 The beneficial effects of SGLT2 inhibitors may be explained, in part, by their blockade of the renin-angiotensin system, 71,72 by Abbreviations: CI, confidence interval; n/N, number of events/number of patients.
FIGURE 3
Univariate regression of the relation between HbA1c change and diabetic retinopathy risk improved glycaemic control and by reduced blood pressure. However, these results are inconclusive and require further research to explore the risk of DR associated with SGLT2 inhibitors.
The results of our network meta-analysis also showed that sulfonylureas might be associated with a higher risk of DR compared to placebo, although the lower limit of the confidence interval is very close to null. This result is inconsistent with direct evidence from the individual trials. The inconsistency might be explained, in part, by the lack of power to detect a statistical difference in the pairwise meta-analysis. In the UKPDS, each 1% reduction in HbA1c with intensive glucose therapies (sulfonylurea or insulin) was associated with a 37% reduction in the risk of retinopathy. 5 However, to our knowledge, no studies have assessed sulfonylurea monotherapy and the risk of retinopathy. 73, 74 Thus, future studies are warranted to confirm our findings.
Two previous observational studies, 9, 10 which had considerable limitations such as lack of duration of individual patient exposure to thiazolidinediones, found an increased risk of macular edema associated with thiazolidinedione therapy. Our analysis did not observe an association between DR risk and thiazolidinediones, which is consistent with the ACCORD eye study. 75, 76 Further studies are needed to examine the risk of DR in the context of thiazolidinediones.
Our meta-analysis of 37 randomized trials has several strengths.
First, we used rigorous methodology to systematically identify and synthesize data. Second, in addition to published reports, our study also included 8 trials that were not published in peer-reviewed journals, but were identified at ClinicalTrials.gov. Third, we carefully compared the data in journal publications and at ClinicalTrials.gov for consistency, and contacted authors to ensure accuracy.
Our meta-analysis has limitations as well. Firstly, none of the included trials was systematically designed to evaluate DR events.
Only 5 trials clearly predefined a DR outcome 8, 13, 14, 25, 26 and the rest may have underreported DR events. Most data for DR endpoints come from adverse event reporting rather than from trial data. Such limitations decrease the validity of our meta-analysis. Second, because of the short-term follow-up in the included clinical trials (median, 1.5 years), there may be insufficient follow-up to fully assess the incidence of DR between intervention and control groups. 67 Furthermore, as prior research suggested that a rapid reduction in HbA1c was associated with progression of microvascular disease, followed by a resolution of symptoms, the data included in our meta-analysis might overestimate this risk and underestimate the long-term overall benefits of HbA1c reduction. Third, the absence of data on grading of DR at baseline and during the trials made it difficult to calculate the actual number of new adverse events. Fewer new events of DR would be reported if a study arm contained a disproportionate number of participants with previously treated retinopathy. In our meta-analysis 5 trials did have a predefined DR outcome, 8, 13, 14, 25, 26 but the methods used to detect and report DR were not clarified. It is more probable that only severe DR would be reported, that is, less severe DR such as mild or moderate non-proliferative DR was probably not reported. Thus, the unclear outcome definition from the included trials might weaken our internal validity. Finally, given the limited number of studies on metformin, α-glucosidase inhibitors, SGLT2 inhibitors, glinides, thiazolidinediones and sulfonylureas included in our meta-analysis, the risk of DR for these classes of drugs remains uncertain.
Our meta-analysis based on current evidence suggests that the risk of DR associated with DPP-4i or GLP-1RA remains uncertain, while some evidence indicates that sulfonylureas may be associated with increased risk of DR. There was no significant difference between SGLT2 inhibitors and risk of DR. However, given that these events may be underreported, and that DR was not systematically assessed as an endpoint, further data from large-scale, well-designed studies and from real-world settings are warranted.
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